May 23rd, 2022 (Earnings Report)Dear Reader,HealthTechMovers.com just identified several healthtech stocks that are expected to release earnings starting today.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Genetron Holdings
Symbol: GTH
Recent Price: $$1.38
Average Analyst Price Target: $10.00 (624.64%)
Market Cap: $$125.03M
Last Year's EPS: -$0.25
Consensus EPS Forecast: -$0.27
Expected Earnings Date: May 22 2022
Recent Analyst Action: Sung Ji, analyst at BTIG, reiterates coverage on Genetron Holdings (GTH) in the Healthcare sector with a Buy rating and a price target of $ 10 (1 month ago).
TipRanks.com also reports that Genetron Holdings currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.00 . The target pricing ranges from a high forecast of $10.00 down to a low forecast of $10.00. Genetron Holdings (GTH)’s last closing price was $$1.38 which would put the average price target at 624.64% upside.Here are 3rd party ratings for GTH:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: n/a, n/a
--------------------------------------------------------------------------
*ReShape Lifesciences
Symbol: RSLS
Recent Price: $$0.82
Average Analyst Price Target: $4.00 (390.20%)
Market Cap: $$12.93M
Last Year's EPS: -$1.32
Consensus EPS Forecast: -$0.35
Expected Earnings Date: May 22 2022
Recent Analyst Action: Anthony Vendetti, analyst at Maxim Group, reiterates coverage on ReShape Lifesciences (RSLS) in the Healthcare sector with a Buy rating and a price target of $ 4 (1 month ago).
TipRanks.com also reports that ReShape Lifesciences currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $4.00 . The target pricing ranges from a high forecast of $4.00 down to a low forecast of $4.00. ReShape Lifesciences (RSLS)’s last closing price was $$0.82 which would put the average price target at 390.20% upside.Here are 3rd party ratings for RSLS:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: n/a, n/a
--------------------------------------------------------------------------
Star Equity Holdings
Symbol: STRR
Recent Price: $$0.78
Average Analyst Price Target: $3.50 (351.50%)
Market Cap: $$11.64M
Last Year's EPS: -$0.35
Consensus EPS Forecast: -$0.15
Expected Earnings Date: May 22 2022
Recent Analyst Action: Tate Sullivan, analyst at Maxim Group, reiterates coverage on Star Equity Holdings (STRR) in the Healthcare sector with a Buy rating and a price target of $ 3.5 (2 months ago).
TipRanks.com also reports that Star Equity Holdings currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $3.50 . The target pricing ranges from a high forecast of $3.50 down to a low forecast of $3.50. Star Equity Holdings (STRR)’s last closing price was $$0.78 which would put the average price target at 351.50% upside.Here are 3rd party ratings for STRR:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 24% (60 out of 253)
--------------------------------------------------------------------------
Agilent
Symbol: A
Recent Price: $$125.13
Average Analyst Price Target: $146.67 (17.21%)
Market Cap: $$37.55B
Last Year's EPS: $0.97
Consensus EPS Forecast: $1.12
Expected Earnings Date: May 23 2022
Recent Analyst Action: Patrick B, analyst at Citigroup, reiterates coverage on Agilent (A) in the Healthcare sector with a Buy rating and a price target of $ 175 (1 week ago).
TipRanks.com also reports that Agilent currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $146.67 . The target pricing ranges from a high forecast of $175.00 down to a low forecast of $130.00. Agilent (A)’s last closing price was $$125.13 which would put the average price target at 17.21% upside.Here are 3rd party ratings for A:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 30% (176 out of 253)
--------------------------------------------------------------------------
Taro Pharmaceutical
Symbol: TARO
Recent Price: $$37.60
Average Analyst Price Target: $73.00 (94.15%)
Market Cap: $$1.41B
Last Year's EPS: -$0.78
Consensus EPS Forecast: $0.88
Expected Earnings Date: May 23 2022
Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on Taro Pharmaceutical (TARO) in the Healthcare sector with a Buy rating and a price target of $ 73 (2 months ago).
TipRanks.com also reports that Taro Pharmaceutical currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $73.00 . The target pricing ranges from a high forecast of $73.00 down to a low forecast of $73.00. Taro Pharmaceutical (TARO)’s last closing price was $$37.60 which would put the average price target at 94.15% upside.Here are 3rd party ratings for TARO:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 42% (147 out of 253)
--------------------------------------------------------------------------
Rubicon Organics
Symbol: ROMJF
Recent Price: $$0.75
Average Analyst Price Target: $2.73 (262.62%)
Market Cap: $$42.15M
Last Year's EPS: -$0.06
Consensus EPS Forecast: ―
Expected Earnings Date: May 23 2022
Recent Analyst Action: Rahul Sarugaser, analyst at Raymond James, reiterates coverage on Rubicon Organics (ROMJF) in the Healthcare sector with a Buy rating and a price target of $ 2.73 (1 month ago).
TipRanks.com also reports that Rubicon Organics currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $2.73 . The target pricing ranges from a high forecast of $2.73 down to a low forecast of $2.73. Rubicon Organics (ROMJF)’s last closing price was $$0.75 which would put the average price target at 262.62% upside.Here are 3rd party ratings for ROMJF:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: n/a, n/a
--------------------------------------------------------------------------
*Editor has position in this security.
To Your Financial Future,
The Editor, HealthTechMovers.com
